Zimmer Biomet stock (US98956P1021): hip and knee specialist updates investors after latest earnings

Zimmer Biomet has reported fresh quarterly figures and updated its outlook, keeping attention on demand for hip and knee implants as elective procedures normalize. What is driving the medtech stock now, and which trends matter for US investors?

Zimmer Biomet, a leading provider of orthopedic implants and surgical technologies, recently updated investors with its latest quarterly results and outlook, drawing renewed attention to the stock as elective procedure volumes continue to normalize after the pandemic. The company reported first-quarter 2026 results on April 25, 2026, with revenue modestly higher year over year and adjusted earnings per share slightly above market expectations, according to Zimmer Biomet press release as of 04/25/2026 and an earnings recap from Reuters as of 04/25/2026.

In reaction to the earnings update and guidance confirmation, Zimmer Biomet shares showed a measured move on the New York Stock Exchange, trading around the mid-100?USD range on April 25, 2026, according to consolidated price data from NYSE as of 04/25/2026. The stock’s performance continues to hinge on trends in hip and knee replacement procedures, pricing dynamics, and hospital capital spending in the United States and other key markets.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zimmer Biomet
• Sector/industry: Medical technology, orthopedic devices
• Headquarters/country: Warsaw, Indiana, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Hip and knee implants, trauma and extremities, surgical robotics and related technologies
• Home exchange/listing venue: New York Stock Exchange (ticker: ZBH)
• Trading currency: US dollar (USD)

Zimmer Biomet: core business model

Zimmer Biomet focuses on designing, manufacturing and marketing orthopedic implants and related technologies that are used mainly in hip and knee replacement surgeries, as well as in trauma, extremities and other musculoskeletal procedures. The business model is built around selling high-value implants and instruments to hospitals and surgery centers, supported by a global network of sales representatives and clinical specialists who work closely with orthopedic surgeons. This high-touch model is common in orthopedics and influences margins, pricing, and competitive dynamics.

A significant portion of Zimmer Biomet’s revenue is generated by elective procedures, particularly primary and revision hip and knee replacements. These procedures tend to be sensitive to hospital staffing levels, reimbursement frameworks and broader macroeconomic conditions, because they can be postponed when health systems face capacity constraints. The company also offers shoulder, sports medicine and trauma products, as well as craniomaxillofacial and thoracic solutions, which diversify its revenue base beyond lower-extremity joints.

In recent years, Zimmer Biomet has expanded into enabling technologies, including surgical planning software, robotic-assisted surgery platforms and navigation systems that aim to improve surgical precision and patient outcomes. These offerings typically carry different margin profiles and longer sales cycles than standard implants, as hospitals often treat them as capital investments. Management has emphasized that digital and robotic solutions are designed to reinforce implant sales over time, creating an integrated ecosystem rather than a standalone hardware business.

The company generates most of its sales in developed markets, with the United States remaining the single largest geography. Contracts with large hospital systems, group purchasing organizations and integrated delivery networks play a major role in determining volume and pricing. Outside the US, Zimmer Biomet sells through a mix of direct sales forces and distributors, adapting to local regulatory requirements and reimbursement systems in Europe and emerging markets.

Main revenue and product drivers for Zimmer Biomet

The strongest revenue drivers for Zimmer Biomet continue to be hip and knee implants, which together represent a substantial share of total sales. In its full-year 2025 report, the company noted that revenue from knees and hips grew at a low- to mid-single-digit percentage rate compared with 2024, supported by more normalized procedure volumes and steady demand in both the United States and international markets, according to the company’s annual filing published on February 15, 2026, as summarized by SEC filing overview as of 02/15/2026.

Within knees, Zimmer Biomet offers a range of implant systems tailored to different patient anatomies and surgeon preferences. Product lines focus on improving range of motion, implant longevity and patient satisfaction, and the company periodically refreshes its portfolio with incremental innovations in materials and design. Hip implants similarly span multiple bearing surfaces and fixation approaches, addressing both cemented and cementless procedures. Because these products are central to orthopedic practices, competition is intense, with rivals such as Stryker and Johnson & Johnson’s DePuy Synthes also investing heavily in innovation and surgeon relationships.

Another important revenue contributor is the trauma and extremities segment, which includes plates, screws, nails and specialized implants for fractures and deformity correction in upper and lower limbs. This segment is influenced not only by elective procedures but also by acute cases resulting from accidents and injuries, which can be less cyclical. As a result, trauma and extremities can provide a degree of resilience when elective volumes fluctuate. Zimmer Biomet has highlighted opportunities in shoulder reconstruction and foot-and-ankle implants, areas that have seen rising demand and new product launches over the past several years, according to product updates referenced in a strategic overview released on March 11, 2026, and summarized by Bloomberg as of 03/11/2026.

Enabling technologies, including robotics and digital tools, represent a smaller but strategically important part of Zimmer Biomet’s portfolio. The company’s robotic-assisted solutions are designed to integrate with its implant systems, allowing surgeons to plan and execute procedures with enhanced accuracy. Hospitals often evaluate these platforms based on potential benefits such as more consistent outcomes, shorter hospital stays and fewer revisions. Over time, successful adoption can strengthen customer loyalty and help differentiate Zimmer Biomet from competitors.

Beyond hardware, the company increasingly emphasizes data and analytics. Digital platforms that capture intraoperative and postoperative data can support clinical decision-making and quality improvement initiatives. They may also become valuable in reimbursement discussions, as payers and providers look for evidence of improved outcomes and cost efficiency. This transition toward data-enabled care aligns with broader trends in medtech and could provide Zimmer Biomet with additional levers to support growth if execution remains consistent.

Industry trends and competitive position

The orthopedic devices industry is shaped by demographic trends, particularly aging populations in developed markets and rising prevalence of osteoarthritis and obesity. These factors support long-term demand for joint replacement procedures, though short-term volumes can fluctuate with economic conditions, reimbursement changes and hospital staffing constraints. Zimmer Biomet operates in a competitive field dominated by a handful of global players, each vying for surgeon loyalty and incremental share gains in hips, knees and trauma.

Pricing pressure is an ongoing consideration. Large hospital systems and procurement organizations often negotiate aggressively on implant pricing, while public and private payers scrutinize procedure costs. At the same time, regulatory requirements for device approvals and post-market surveillance can be demanding, adding complexity and cost. Zimmer Biomet must balance investment in research and development with efforts to maintain attractive operating margins, a dynamic that investors monitor closely during each earnings cycle.

Technological innovation is another key trend. Robotic-assisted surgery, navigation tools and AI-supported planning software are gradually being incorporated into orthopedic practices, though adoption varies by region and hospital. Zimmer Biomet’s strategy to pair implants with integrated digital platforms reflects a view that technology can deepen customer relationships and create switching costs. Success in this area depends on demonstrating clinical benefits and ease of use, which are evaluated by surgeons, administrators and payers alike.

Why Zimmer Biomet matters for US investors

For US investors, Zimmer Biomet is relevant both as a pure-play exposure to orthopedic devices and as part of the broader US medtech landscape. The company is listed on the New York Stock Exchange under the ticker ZBH and is included in several healthcare and medical technology indices that are commonly tracked by institutional investors. Its performance can influence, and be influenced by, sentiment toward the wider medical devices sector in the United States.

US procedure volumes are particularly important because the country represents Zimmer Biomet’s largest market by revenue. Trends in Medicare reimbursement for joint replacement, including bundled payment programs and outpatient migration, can have meaningful effects on hospital behavior and device purchasing patterns. Investors often watch how Zimmer Biomet adapts to these shifts, for example by supporting ambulatory surgery center workflows or tailoring product offerings to different care settings, according to policy commentary summarized by Fierce Biotech as of 03/05/2026.

From a portfolio construction standpoint, Zimmer Biomet tends to be viewed as a company with exposure to structural healthcare demand rather than short-term consumer cycles. Nevertheless, results can be sensitive to execution on product launches, competitive responses and regulatory developments, including device recalls or quality system observations. These factors, combined with currency movements and macroeconomic trends, can contribute to share price volatility that US investors consider when evaluating risk.

Conclusion

Zimmer Biomet remains a central player in global orthopedics, with hip and knee implants at the heart of its business and an expanding portfolio of trauma, extremities and enabling technologies. The latest quarterly report and outlook underscore how closely the company’s performance is tied to procedure volumes, pricing dynamics and hospital capital spending, particularly in the United States. While long-term demand for joint replacement is supported by demographic trends, investors continue to track execution on innovation, competitive positioning and regulatory compliance. The stock’s reaction to recent earnings highlights how incremental changes in guidance or margin expectations can influence sentiment, even in a sector anchored by structural healthcare needs.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.